Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
暂无分享,去创建一个
Y. Qi | B. Ebert | Xiaoping Su | K. Bhalla | T. Kadia | Koichi Takahashi | N. Daver | C. Dinardo | J. Khoury | S. Boettcher | G. Mcgeehan | W. Fiskus | John A. Davis | K. Sasaki | C. Mill | C. Birdwell | Qi Jin | G. McGeehan | Christopher P. Mill
[1] M. Konopleva,et al. Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax , 2021, Cancer.
[2] M. Andreeff,et al. Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML. , 2021, Blood.
[3] M. Konopleva,et al. Outcomes in patients with newly diagnosed TP53‐mutated acute myeloid leukemia with or without venetoclax‐based therapy , 2021, Cancer.
[4] M. Andreeff,et al. Therapeutic implications of menin inhibition in acute leukemias , 2021, Leukemia.
[5] Michael R. Green,et al. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells , 2021, Blood Cancer Journal.
[6] W. El-Deiry,et al. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. , 2021, Biochimica et biophysica acta. Reviews on cancer.
[7] Yongcheng Song,et al. Structure, function and inhibition of critical protein–protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins , 2021, Journal of Hematology & Oncology.
[8] T. Cierpicki,et al. Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations. , 2020, Blood.
[9] M. Konopleva,et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. , 2020, Blood advances.
[10] B. Falini,et al. NPM1-mutated acute myeloid leukemia: from bench to bedside. , 2020, Blood.
[11] S. Armstrong,et al. Synergistic Targeting of FLT3 Mutations in AML via Combined Menin-MLL and FLT3 Inhibition. , 2020, Blood.
[12] B. Yan,et al. AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy. , 2020, Experimental hematology.
[13] M. Levis,et al. Gilteritinib: potent targeting of FLT3 mutations in AML. , 2020, Blood advances.
[14] S. Armstrong,et al. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia , 2020, Science.
[15] K. Ross,et al. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. , 2019, Cancer cell.
[16] C. Schmitt,et al. Cellular Senescence: Defining a Path Forward , 2019, Cell.
[17] Donna Neuberg,et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies , 2019, Science.
[18] Jing Wang,et al. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models , 2019, Haematologica.
[19] K. Rajapakshe,et al. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells , 2019, Blood Cancer Journal.
[20] P. Qiu,et al. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML , 2018, Leukemia.
[21] S. Armstrong,et al. HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis. , 2018, Cancer cell.
[22] E. Kjeldsen,et al. Systematic evaluation of signal-to-noise ratio in variant detection from single cell genome multiple displacement amplification and exome sequencing , 2018, BMC Genomics.
[23] Charles Y. Lin,et al. Mutant NPM1 Maintains the Leukemic State through HOX Expression. , 2018, Cancer cell.
[24] T. Pabst,et al. The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia , 2018, Cancers.
[25] T. Cierpicki,et al. Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction. , 2018, Journal of medicinal chemistry.
[26] Scott W. Lowe,et al. Putting p53 in Context , 2017, Cell.
[27] V. Rotter,et al. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy. , 2017, Blood.
[28] Jian Du,et al. Preclinical characterization of abemaciclib in hormone receptor positive breast cancer , 2017, Oncotarget.
[29] A. Ashkenazi,et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors , 2017, Nature Reviews Drug Discovery.
[30] F. Nigsch,et al. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia , 2017, Leukemia.
[31] Bo Wen,et al. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. , 2015, Cancer cell.
[32] X. Hua,et al. Menin: a scaffold protein that controls gene expression and cell signaling. , 2013, Trends in biochemical sciences.
[33] C. Allis,et al. Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. , 2010, Molecular cell.
[34] Jiaying Tan,et al. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. , 2010, Cancer cell.
[35] M. Cleary,et al. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. , 2010, Cancer cell.
[36] Akihiko Yokoyama,et al. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. , 2008, Cancer cell.
[37] R. Humphries,et al. Unraveling the crucial roles of Meis1 in leukemogenesis and normal hematopoiesis. , 2007, Genes & development.
[38] Scott A. Armstrong,et al. MLL translocations, histone modifications and leukaemia stem-cell development , 2007, Nature Reviews Cancer.
[39] D. Kioussis,et al. Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. , 2007, Cell stem cell.
[40] Matthew Meyerson,et al. The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis , 2005, Cell.
[41] R. Humphries,et al. Hox regulation of normal and leukemic hematopoietic stem cells , 2005, Current opinion in hematology.
[42] O. Rozenblatt-Rosen,et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[43] R. D. Hanson,et al. MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[44] M. Meyerson,et al. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia. , 2019, Experimental hematology.